Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Bayer Bang & Olufsen Medicom |
---|---|
Information provided by: | Bayer |
ClinicalTrials.gov Identifier: | NCT00470886 |
The purpose of this study is to asses the efficacy and safety of Telmisartan depending on the use of an electronic therapy monitoring device (HelpingHand) in a real life setting and to asses patients compliance to the therapy with Telmisartan in relation to use of electronic therapy monitoring device.
Condition | Intervention |
---|---|
Hypertension |
Drug: Telmisartan (BAY68-9291) |
Study Type: | Observational |
Study Design: | Cohort, Prospective |
Official Title: | A Non-Interventional, Post-Marketing Surveillance, Phase IV Study to Assess Compliance With Antihypertensive Telmisartan Therapy |
Estimated Enrollment: | 5000 |
Study Start Date: | April 2007 |
Estimated Study Completion Date: | October 2009 |
Estimated Primary Completion Date: | October 2009 (Final data collection date for primary outcome measure) |
Groups/Cohorts | Assigned Interventions |
---|---|
Group 1 |
Drug: Telmisartan (BAY68-9291)
Primary care clinic hypertensive patients for whom physician decided to start the treatment with telmisartan
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Primary care clinic hypertensive patients for whom physician decided to start the treatment with telmisartan
Inclusion Criteria:
Exclusion Criteria:
Contact: Bayer Clinical Trials Contact | clinical-trials-contact@bayerhealthcare.com |
Poland | |
Recruiting | |
Many locations, Poland | |
Slovakia | |
Recruiting | |
Many locations, Slovakia |
Study Director: | Bayer Study Director | Bayer |
Responsible Party: | Bayer Sp. z o.o. ( Medical Director ) |
Study ID Numbers: | 12827, KL0710PL, KL0710SK, 14237, COAST |
Study First Received: | May 7, 2007 |
Last Updated: | April 15, 2009 |
ClinicalTrials.gov Identifier: | NCT00470886 History of Changes |
Health Authority: | Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products; United States: Food and Drug Administration |
Angiotensin II Type 1 Receptor Blockers Vascular Diseases Angiotensin-Converting Enzyme Inhibitors Cardiovascular Agents Telmisartan |
Angiotensin II Antihypertensive Agents Protease Inhibitors Hypertension |
Molecular Mechanisms of Pharmacological Action Vascular Diseases Enzyme Inhibitors Cardiovascular Agents Antihypertensive Agents Pharmacologic Actions Protease Inhibitors |
Angiotensin II Type 1 Receptor Blockers Therapeutic Uses Angiotensin-Converting Enzyme Inhibitors Cardiovascular Diseases Telmisartan Hypertension |